152 related articles for article (PubMed ID: 38298058)
1. Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis.
Chang C; Vong C; Wang X; Hazra A; Diehl A; Nicholas T; Mukherjee A
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):599-611. PubMed ID: 38298058
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Ruperto N; Brunner HI; Zuber Z; Tzaribachev N; Kingsbury DJ; Foeldvari I; Horneff G; Smolewska E; Vehe RK; Hazra A; Wang R; Mebus CA; Alvey C; Lamba M; Krishnaswami S; Stock TC; Wang M; Suehiro R; Martini A; Lovell DJ; ;
Pediatr Rheumatol Online J; 2017 Dec; 15(1):86. PubMed ID: 29282090
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N; Brunner HI; Synoverska O; Ting TV; Mendoza CA; Spindler A; Vyzhga Y; Marzan K; Grebenkina L; Tirosh I; Imundo L; Jerath R; Kingsbury DJ; Sozeri B; Vora SS; Prahalad S; Zholobova E; Butbul Aviel Y; Chasnyk V; Lerman M; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Posner HB; Kanik KS; Wouters A; Chang C; Zhang R; Lazariciu I; Hsu MA; Suehiro RM; Martini A; Lovell DJ;
Lancet; 2021 Nov; 398(10315):1984-1996. PubMed ID: 34767764
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
.
Xie R; Deng C; Wang Q; Kanik KS; Nicholas T; Menon S
Int J Clin Pharmacol Ther; 2019 Sep; 57(9):464-473. PubMed ID: 31319908
[TBL] [Abstract][Full Text] [Related]
6. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
Gandhi Y; Passarell JA; Roy A; Murthy B
J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
[TBL] [Abstract][Full Text] [Related]
7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Bioequivalence of 2 Immediate-Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions.
Li X; Liu L; Deng Y; Li Y; Zhang P; Wang Y; Xu B; Feng J; Huang L
Clin Pharmacol Drug Dev; 2021 May; 10(5):535-541. PubMed ID: 32770665
[TBL] [Abstract][Full Text] [Related]
9. A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis.
Decker RL; Steven Ernest C; Radtke DB; Wang R; Araújo J; Keller SY; Zhang X
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):970-981. PubMed ID: 38532270
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S
J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
[TBL] [Abstract][Full Text] [Related]
12. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
[TBL] [Abstract][Full Text] [Related]
13. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.
Toublanc N; Sargentini-Maier ML; Lacroix B; Jacqmin P; Stockis A
Clin Pharmacokinet; 2008; 47(5):333-41. PubMed ID: 18399714
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and bioequivalence of tofacitinib 5 mg in healthy Korean male subjects.
Lee JH; Jeon JY; Jang K; Kang SK; Kwak YG; Moon SJ; Kim MG
Int J Clin Pharmacol Ther; 2024 Mar; 62(3):142-148. PubMed ID: 38174885
[TBL] [Abstract][Full Text] [Related]
17. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Pacheco-Tena C; Louw I; Vega-Cornejo G; Spindler AJ; Kingsbury DJ; Schmeling H; Borzutzky A; Cuttica R; Inman CJ; Malievskiy V; Scott C; Keltsev V; Terreri MT; Viola DO; Xavier RM; Fernandes TAP; Velázquez MDRM; Henrickson M; Clark MB; Bensley KA; Li X; Lo KH; Leu JH; Hsu CH; Hsia EC; Xu Z; Martini A; Lovell DJ;
Rheumatology (Oxford); 2021 Oct; 60(10):4495-4507. PubMed ID: 33493312
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh.
Rahman MM; Laila K; Rahman SA
Int J Rheum Dis; 2022 Jun; 25(6):678-684. PubMed ID: 35435319
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Infliximab in Children with Juvenile Idiopathic Arthritis.
Nassar-Sheikh Rashid A; Schonenberg-Meinema D; Berends SE; van den Berg JM; Mathôt RAA
Ther Drug Monit; 2022 Apr; 44(2):301-307. PubMed ID: 34292215
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
